Lipoid pneumonia historical perspective

Jump to navigation Jump to search

Lipoid pneumonia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Lipoid pneumonia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Lipoid pneumonia historical perspective On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Lipoid pneumonia historical perspective

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Lipoid pneumonia historical perspective

CDC on Lipoid pneumonia historical perspective

Lipoid pneumonia historical perspective in the news

Blogs on Lipoid pneumonia historical perspective

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Lipoid pneumonia historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ramyar Ghandriz MD[2]

Overview

In 1925, G. F. LAUGHLEN, M.D. was the first physician to describe lipoid pneumonia. He first interacted with the disease by routine autopsy at the Toronto, Ontario hospital for sick children. He described grayish red nodules at the autopsy with three types of exudates, found out mononuclear cells which were unexpected in the exudates. In 1949 McDonald et al described endogenous lipoid pneumonia for the first time. He observed so-called "obstructive pneumonia" in patients with lung neoplasms.

Historical Perspective

Discovery

Important landmark

Following are important landmark events that shows how aspiration pneumonia became an important entity of critical care:[4][5][3][6][7][8]

Year Events
460 BC–380 BC Hippocrates described pneumonia.
1138–1204 AD Maimonides wrote about pneumonia as "The basic symptoms which occur in pneumonia and which are never lacking are as follows: acute fever, sticking pleuritic pain in the side, short rapid breaths, serrated pulse, and cough."
1875 Edwin Klebs identified bacteria in the airways of individuals who died from pneumonia.
1848 Carl Friedländer identified the two common bacteria such as Streptococcus pneumoniae and Klebsiella pneumoniae that cause pneumonia.
1893 Veillon was first to write about the role of anaerobic bacteria in aspiration pneumonia.
1896 Roentgen described x-rays.
1918 Sir William Osler, known as "the father of modern medicine," appreciated the morbidity and mortality of pneumonia, describing it as the "captain of the men of death."
1927 Smith was first to clearly show anaerobic bacterial growth in animal models suffered from aspiration pneumonia.
1929 Drinker and Shaw announced the invention of the iron lung during the
 polio epidemic.
1985 Specimens collected from patients with aspiration pneumonia were vastly cultured and it was called anaerobic bandwagon.

Lipoid pneumonia outbreak

References

  1. Laughlen GF (July 1925). "Studies on Pneumonia Following Naso-Pharyngeal Injections of Oil". The American Journal of Pathology. 1 (4): 407–414.1. PMC 1931653. PMID 19969662.
  2. McDONALD JR, HARRINGTON SW, CLAGETT OT (1949). "Obstructive pneumonitis of neoplastic origin; an interpretation of one form of so-called atelectasis and its correlation according to presence of absence of sputum". J Thorac Surg. 18 (1): 97–112, disc., 122. PMID 18110247.
  3. 3.0 3.1 Marik PE, Careau P (1999). "The role of anaerobes in patients with ventilator-associated pneumonia and aspiration pneumonia: a prospective study". Chest. 115 (1): 178–83. PMID 9925081.
  4. Japanese Respiratory Society (2009). "Aspiration pneumonia". Respirology. 14 Suppl 2: S59–64. doi:10.1111/j.1440-1843.2009.01578.x. PMID 19857224.
  5. Almirall J, Cabré M, Clavé P (2012). "Complications of oropharyngeal dysphagia: aspiration pneumonia". Nestle Nutr Inst Workshop Ser. 72: 67–76. doi:10.1159/000339989. PMID 23052002.
  6. Cordier JF, Cottin V (2013). "Neglected evidence in idiopathic pulmonary fibrosis: from history to earlier diagnosis". Eur Respir J. 42 (4): 916–23. doi:10.1183/09031936.00027913. PMID 23598958.
  7. Shi X, Zheng J, Yan T (2018). "Computational redesign of human respiratory syncytial virus epitope as therapeutic peptide vaccines against pediatric pneumonia". J Mol Model. 24 (4): 79. doi:10.1007/s00894-018-3613-z. PMID 29500665.
  8. Shen CF, Wang SM, Ho TS, Liu CC (2017). "Clinical features of community acquired adenovirus pneumonia during the 2011 community outbreak in Southern Taiwan: role of host immune response". BMC Infect Dis. 17 (1): 196. doi:10.1186/s12879-017-2272-5. PMC 5341368. PMID 28270104.
  9. "Outbreak of Electronic-Cigarette–Associated Acute Lipoid Pneumonia — North Carolina, July–August 2019 | MMWR".
  10. "Outbreak of Electronic-Cigarette–Associated Acute Lipoid Pneumonia — North Carolina, July–August 2019 | MMWR".
  11. "CDC vaping illness investigation: Vitamin E acetate linked to THC may be to blame - CNN".

Template:WH Template:WS